Skip to main content

Table 1 Planned, preventive (pSIA) SIA schedules used in the global model before and after OPV2 cessation in OPV-using blocks after interruption of indigenous wild poliovirus transmission in each block (based on Duintjer Tebbens et al. (2015) [20])

From: The differential impact of oral poliovirus vaccine formulation choices on serotype-specific population immunity to poliovirus transmission

Time period

RI coverage (POL3)

SIA schedule showing: vaccine (day(s) of year)

Before tOPV intensification on January 1, 2015

0.05 or 0.1

tOPV (0, 40); bOPV (80, 140, 240, 300)

0.3

tOPV (0, 40); bOPV (80, 140, 240)

0.6 (R0 ≤ 10)

tOPV (0); bOPV (60, 120)

0.6 (R0 > 10)

tOPV (0, 40); bOPV (80, 140, 240)

0.9

tOPV (0)

0.98 (R0 ≤ 10)

No SIAs

0.98 (R0 > 10)

tOPV (0)

During tOPV intensification (January 1, 2015 to April 1, 2016)

0.05 or 0.1

tOPV (0, 40, 80, 300); bOPV (140, 240)

0.3

tOPV (0, 40, 80); bOPV (140, 240)

0.6 (R0 ≤ 10)

tOPV (0, 60); bOPV (120)

0.6 (R0 > 10)

tOPV (0, 40, 80); bOPV (140, 240)

0.9

tOPV (0)

0.98 (R0 ≤ 10)

No SIAs

0.98 (R0 > 10)

tOPV (0)

After tOPV intensification (April 1, 2016 to OPV13 cessation)

0.05 or 0.1

bOPV (0, 40, 80, 140, 240, 300)

0.3

bOPV (0, 40, 80, 140, 240)

0.6 (R0 ≤ 10)

bOPV (0, 60, 120)

0.6 (R0 > 10)

bOPV (0, 40, 80, 140, 240)

0.9

bOPV (0)

0.98 (R0 ≤ 10)

No SIAs

0.98 (R0 > 10)

bOPV (0)